Overview of Global New Drugs in 2009: Anti -cancer drugs are prominent
Release time: 2010-06-03 & nbsp & nbsp & nbsp Source:
According to the latest research, it shows，There are 25 new active substances (NASS), the world's first listing worldwide (only including new chemical entities or biological preparations，excluding new formulas and popular influenza vaccines)，20%reduced compared to 31 products in 2008，It is also lower than the average of 29 products per year in the past 9 years。The author of this article summarizes the listing of new global drugs in 2009，Point out that although the growth rate of new products around the world slows down，But there are many anticancer drugs、New products of diabetic drugs emerge，Pharmaceutical companies have not slowed down the pace of R & D。At the same time, the author will also summarize the first new active material summary My stake betting appof the world in 2009，Reference for people in the industry。
Although compared with previous years，In 2009，But there is still a variety of attention。7 countries around the world became the preferred market for 25 new activated substances in 2009，They are the United States、UK、Germany、Japan、Finland、Austria and Denmark。14 products choose the United States as the world's first market，It shows that the United States still firmly occupies the most popular pharmaceutical market.，Germany、UK and Japan followed closely。
From the treatment category，2009 Anti -Cancer Drug (5) occupied a leading position，Allos Therapeutics The company's folic acid metabolic simulation inhibitor FOLOTYN became the world's first approved recurrence or refractory perimeter T cell lymphoma (PTCL) treatment product，The other 4 anticancer drugs are Huoling Pharmaceutical Company's treatment of prostate cancer, gonadotropin release hormone receptor (GNRH) antagonist Firmagon; GenMab/GlaxoSmithk company treats refractory chronic lymphocytosis ( CLL) Anti -CD20 monoclonal antibody arzerra; Fisen Jous/Trion Pharma's monoclonal antibody Removab for the treatment of pancreatic cancer; Glaxozulosk's oral multi -targeting tyrosine kinase inhibitors for advanced renal cancer Votrient。Anti -cancer drugs are becoming a key area for global drug research and development，According to the data released by the 2009 U.S. Pharmaceutical Merchants Federation，There are 1512 anticancer drugs under the global research。
2009，Two new "faces" in the "crowded" type stake betting app2 diabetic therapy products appeared，That is Nuo and Nord's GLP-1 analog of Victoza and Bellet Schimibao Company and Astrikon's di-peptidase IV (DPP-4) inhibitors osleyza。To obtain the approval of the US Food and Drug Administration (FDA)，These two products must pass the new cardiovascular safety test proposed by the FDA。After hard supervision procedures，Victoza's label in the United States adds a "black frame" warning of thyroid cancer risk，But the product's European prescription information is not mentioned in the information that may be related to cancer。Victoza's competitor is Amylin /Lili Lili Company listed in 2005 by Byetta，The latter is the first GLP-1 analog of GLP-1，and the product has no cancer warning。ONGLYZA will start with the two other DPP-IV inhibitors to fight the market，They are Galvus of Novartis and Januvia。
Johnson & Johnson has 3 new products standing out in 2009，Among them, Priligy is Janssen-Cilag (j under His Majesty Johnson&J) Company's product，The first drug to treat premature ejaculation in Finland。This product is selective serumin 5 used by "on -demand" - HT Reconstruction inhibitor (SSRI)。The same year，Yu Johnson's subsidiary Centocor Orthobiotech Simponi developed (single cloning antibody for anti -tumor necrosis factor) in the United States，For the treatment of rheumatoid arthritis。The third new product of Johnson & Johnson is nucynta，Developed by Grünenthal Company。This product has a dual analgesic effect ?? Abbey drugs (anesthetic) and non -opioids activate the brain、Spinal cord and gastrointestinal opioid receptor plays Stake Sports Bettinga role; by suppressing the re -intake of the brain's norepinephinxin substance (renewal of the adrenaline of the norepinenium), it plays an analgesic effect。Research indication，Nucynta also has the effect of hydroxyl ketone similar to strong opioid drugs，But the side effects should be small。
Novartis was absent from the listing of new products in 2008，In 2009, 2 new active substances rolled the soil。Except for rare autologous inflammatory diseases Cryopyrin related cyclical syndrome (CAPS) therapy products Ilaris，The company launched a long-acting β2-adrenaline receptor agonist (LABA) onbrez for chronic obstructive pneumonia (COPD) treatment Breezhaler.
In 2009, Pfizer and Merck, which created the largest acquisition operation in modern times, failed to enter the list after acquiring Wyeth and Xianling Yaya。Dan Merck has obtained atypical anti -psychiatric drug Saphris through acquisition，This product was launched in October last year，Used to treat schizophrenia and bipolar disorders。Pfizer obtained β-lactam antibiotic Tebipenem by acquiring Wyeth，The company also purchased the co -operating right of BESIVANCE of Donornone, which cooperates to promote doctors。
Another，2009，Some products also attract attention ----
Japanese Takeda's gout therapy products ULORIC listing。Takeda claims that the product has filled the 40 -year blank of gout treatment。
2009 new generation of emergency contraceptives also debuted。France HRA Pharma's Ellaone is allowed to be listed in the European Union，Become the first in the world to be approved in 120 hours without protective behavior contraceptive stake online sports bettingpills，and other contraceptives based on Zuo Nuo Gormone must be used in 72 hours after sexual behavior。
Sanofi-Avant's product Multaq finally came out after several years of delay。This product is approved for sinus arrhythmia or cardiovascular disease with patients with paroxysmal or persistent atrial fiber fibrillation (AF) or atrium flushing (AFL)。
To sum up，2009 Global pharmaceutical companies did not slow down the pace of new drugs。
Although compared with previous years，In 2009，But there is still a variety of attention。7 countries around the world became the preferred market for 25 new activated substances in 2009，They are the United States、UK、Germany、Japan、Finland、Austria and Denmark。14 products choose the United States as the world's first market，It shows that the United States still firmly occupies the most popular pharmaceutical market.，Germany、UK and Japan followed closely。
From the treatment category，2009 Anti -Cancer Drug (5) occupied a leading position，Allos Therapeutics The company's folic acid metabolic simulation inhibitor FOLOTYN became the world's first approved recurrence or refractory perimeter T cell lymphoma (PTCL) treatment product，The other 4 anticancer drugs are Huoling Pharmaceutical Company's treatment of prostate cancer, gonadotropin release hormone receptor (GNRH) antagonist Firmagon; GenMab/GlaxoSmithk company treats refractory chronic lymphocytosis ( CLL) Anti -CD20 monoclonal antibody arzerra; Fisen Jous/Trion Pharma's monoclonal antibody Removab for the treatment of pancreatic cancer; Glaxozulosk's oral multi -targeting tyrosine kinase inhibitors for advanced renal cancer Votrient。Anti -cancer drugs are becoming a key area for global drug research and development，According to the data released by the 2009 U.S. Pharmaceutical Merchants Federation，There are 1512 anticancer drugs under the global research。
2009，Two new "faces" in the "crowded" type stake betting app2 diabetic therapy products appeared，That is Nuo and Nord's GLP-1 analog of Victoza and Bellet Schimibao Company and Astrikon's di-peptidase IV (DPP-4) inhibitors osleyza。To obtain the approval of the US Food and Drug Administration (FDA)，These two products must pass the new cardiovascular safety test proposed by the FDA。After hard supervision procedures，Victoza's label in the United States adds a "black frame" warning of thyroid cancer risk，But the product's European prescription information is not mentioned in the information that may be related to cancer。Victoza's competitor is Amylin /Lili Lili Company listed in 2005 by Byetta，The latter is the first GLP-1 analog of GLP-1，and the product has no cancer warning。ONGLYZA will start with the two other DPP-IV inhibitors to fight the market，They are Galvus of Novartis and Januvia。
Johnson & Johnson has 3 new products standing out in 2009，Among them, Priligy is Janssen-Cilag (j under His Majesty Johnson&J) Company's product，The first drug to treat premature ejaculation in Finland。This product is selective serumin 5 used by "on -demand" - HT Reconstruction inhibitor (SSRI)。The same year，Yu Johnson's subsidiary Centocor Orthobiotech Simponi developed (single cloning antibody for anti -tumor necrosis factor) in the United States，For the treatment of rheumatoid arthritis。The third new product of Johnson & Johnson is nucynta，Developed by Grünenthal Company。This product has a dual analgesic effect ?? Abbey drugs (anesthetic) and non -opioids activate the brain、Spinal cord and gastrointestinal opioid receptor plays Stake Sports Bettinga role; by suppressing the re -intake of the brain's norepinephinxin substance (renewal of the adrenaline of the norepinenium), it plays an analgesic effect。Research indication，Nucynta also has the effect of hydroxyl ketone similar to strong opioid drugs，But the side effects should be small。
Novartis was absent from the listing of new products in 2008，In 2009, 2 new active substances rolled the soil。Except for rare autologous inflammatory diseases Cryopyrin related cyclical syndrome (CAPS) therapy products Ilaris，The company launched a long-acting β2-adrenaline receptor agonist (LABA) onbrez for chronic obstructive pneumonia (COPD) treatment Breezhaler.
In 2009, Pfizer and Merck, which created the largest acquisition operation in modern times, failed to enter the list after acquiring Wyeth and Xianling Yaya。Dan Merck has obtained atypical anti -psychiatric drug Saphris through acquisition，This product was launched in October last year，Used to treat schizophrenia and bipolar disorders。Pfizer obtained β-lactam antibiotic Tebipenem by acquiring Wyeth，The company also purchased the co -operating right of BESIVANCE of Donornone, which cooperates to promote doctors。
Another，2009，Some products also attract attention ----
Japanese Takeda's gout therapy products ULORIC listing。Takeda claims that the product has filled the 40 -year blank of gout treatment。
2009 new generation of emergency contraceptives also debuted。France HRA Pharma's Ellaone is allowed to be listed in the European Union，Become the first in the world to be approved in 120 hours without protective behavior contraceptive stake online sports bettingpills，and other contraceptives based on Zuo Nuo Gormone must be used in 72 hours after sexual behavior。
Sanofi-Avant's product Multaq finally came out after several years of delay。This product is approved for sinus arrhythmia or cardiovascular disease with patients with paroxysmal or persistent atrial fiber fibrillation (AF) or atrium flushing (AFL)。
To sum up，2009 Global pharmaceutical companies did not slow down the pace of new drugs。
